Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFC 5128

Next Previous
Drug Profile

AFC 5128

Alternative Names: AFC-5128; AFC-5261

Latest Information Update: 27 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affectis Pharmaceuticals
  • Developer Affectis Pharmaceuticals; Charcot-Marie-Tooth Association; Merck Serono
  • Class
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis; Neuropathic pain
  • No development reported Charcot-Marie-Tooth disease

Most Recent Events

  • 11 Oct 2023 Preclinical development is ongoing Germany for multiple sclerosis and neuropathic pain
  • 11 Oct 2023 Pharmacodynamics data from a preclinical trial in multiple sclerosis and neuropathic pain presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2023)
  • 28 May 2019 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in Germany (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top